-
DE
Retatrutide – Triple Agonist for Obesity Treatment
Retatrutide is an investigational drug for obesity and type 2 diabetes that simultaneously activates three hormone receptors for powerful metabolic effects.
Add as Preferred SourceThings worth knowing about "Retatrutide"
Retatrutide is an investigational drug for obesity and type 2 diabetes that simultaneously activates three hormone receptors for powerful metabolic effects.
What is Retatrutide?
Retatrutide is a triple hormone receptor agonist currently under clinical investigation. It simultaneously activates three distinct receptors: the GLP-1 receptor (glucagon-like peptide-1), the GIP receptor (glucose-dependent insulinotropic polypeptide), and the glucagon receptor. This unique triple mechanism is designed to produce superior weight loss and improved blood glucose control compared to existing therapies.
Indications
Retatrutide is primarily being investigated for the following conditions:
- Obesity and overweight with associated health risks
- Type 2 diabetes mellitus with inadequate glycemic control
- Components of metabolic syndrome such as hypertension and dyslipidemia
Mechanism of Action
The pharmacological action of retatrutide is based on the simultaneous activation of three incretin and metabolic hormone receptors:
GLP-1 Receptor Activation
Stimulation of the GLP-1 receptor promotes glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite. These effects lead to improved blood sugar control and reduced caloric intake.
GIP Receptor Activation
The GIP receptor (glucose-dependent insulinotropic polypeptide) amplifies insulin-stimulating effects and contributes to adipose tissue regulation. The combined GLP-1 and GIP activation has already been demonstrated successfully with tirzepatide.
Glucagon Receptor Activation
The additional activation of the glucagon receptor increases energy expenditure and promotes fat breakdown (lipolysis) in the liver. This feature distinguishes retatrutide from already-approved agents such as semaglutide or tirzepatide and may account for its substantially greater weight reduction potential.
Clinical Studies and Efficacy
A Phase 2 trial published in 2023 in The New England Journal of Medicine demonstrated remarkable results for retatrutide:
- Patients with obesity achieved an average body weight reduction of up to 24.2% of baseline weight after 48 weeks of treatment.
- These results surpassed previously reported outcomes with GLP-1 and dual GIP/GLP-1 agonists over comparable study periods.
- Significant improvements in blood glucose levels, lipid profiles, and blood pressure were also observed.
Dosage and Administration
Retatrutide is administered as a subcutaneous injection (under the skin), typically once weekly. Various dosages have been evaluated in clinical trials, with dose escalation strategies employed to improve tolerability. Definitive dosing recommendations for clinical use are still being determined in ongoing Phase 3 trials.
Side Effects
Side effects observed in clinical studies are similar to those of other GLP-1-based agents:
- Gastrointestinal complaints: Nausea, vomiting, diarrhea, and constipation are the most frequent adverse effects, particularly at the start of therapy.
- Decreased appetite
- Potential interactions with other medications, especially other antidiabetic agents
- Elevated heart rate and gallbladder-related issues have been observed in rare cases.
The complete safety profile continues to be evaluated in ongoing Phase 3 studies.
Approval Status
As of now, retatrutide is not yet approved and remains in clinical development. Eli Lilly and Company is developing the compound and conducting Phase 3 trials to confirm its safety and efficacy in larger patient populations. A potential marketing authorization is anticipated in the second half of the 2020s.
References
- Jastreboff AM et al. - Triple-Hormone-Receptor Agonist Retatrutide for Obesity - a Phase 2 Trial. The New England Journal of Medicine, 2023. DOI: 10.1056/NEJMoa2301972
- Eli Lilly and Company - Retatrutide Clinical Development Program. clinicaltrials.gov (NCT05882045), 2024.
- Nauck MA, D'Alessio DA - Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regarding glycaemic control and body weight reduction. Cardiovascular Diabetology, 2022. DOI: 10.1186/s12933-022-01604-7
Building Blocks for a Healthy Life
As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.
Skip product gallery
Subscription available
Floral
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®30 lozenges
Regular price:
22,90 €
Discount
Subscription available
Lactoferrin 60 Capsules
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
60 Capsules
Sale price:
50,00 €
Regular price:
59,90 €
Subscription available
Multivitamin Mineral Complex
Daily basic supply: the complete spectrum of micronutrients
Natural multivitamin complex for the immune system, energy, and central body functions
30 Capsules
Regular price:
29,90 €
Subscription available
Natural Iron
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
30 Capsules
Regular price:
35,90 €
Most read entries
3 Posts in this encyclopedia categoryMagnesiumcarbonat
Magnesiumcarbonat ist eine anorganische Magnesiumverbindung mit säure-neutralisierender (antazidischer) Wirkung. Erfahre mehr über Vorteile, Einsatzgebiete und Unterschiede zu besser resorbierbaren Magnesiumformen.
Calorie content
The choice of food influences our energy intake. The calorie content varies greatly - some provide little energy, others a lot.
Cologne list
The Cologne List ® is an important initiative in competitive sports that offers athletes guidance in the selection of nutritional supplements.